What is the share price of Norris Medicines Ltd (NORRIS) today?
The share price of NORRIS as on 10th July 2025 is ₹17.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Norris Medicines Ltd (NORRIS) share?
The past returns of Norris Medicines Ltd (NORRIS) share are- Past 1 week: -5.49%
- Past 1 month: -3.24%
- Past 3 months: 10.62%
- Past 6 months: -5.60%
- Past 1 year: 20.41%
- Past 3 years: 108.24%
- Past 5 years: 429.94%
What are the peers or stocks similar to Norris Medicines Ltd (NORRIS)?
The peers or stocks similar to Norris Medicines Ltd (NORRIS) include:What is the market cap of Norris Medicines Ltd (NORRIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Norris Medicines Ltd (NORRIS) is ₹17.70 Cr as of 10th July 2025.What is the 52 week high and low of Norris Medicines Ltd (NORRIS) share?
The 52-week high of Norris Medicines Ltd (NORRIS) is ₹27.74 and the 52-week low is ₹12.57.What is the PE and PB ratio of Norris Medicines Ltd (NORRIS) stock?
The P/E (price-to-earnings) ratio of Norris Medicines Ltd (NORRIS) is -14.28. The P/B (price-to-book) ratio is -1.30.Which sector does Norris Medicines Ltd (NORRIS) belong to?
Norris Medicines Ltd (NORRIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Norris Medicines Ltd (NORRIS) shares?
You can directly buy Norris Medicines Ltd (NORRIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Norris Medicines Ltd
NORRIS Share Price
17.701.17% (-0.21)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NORRIS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NORRIS Performance & Key Metrics
NORRIS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -14.63 | -1.30 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
NORRIS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NORRIS Company Profile
Norris Medicines is engaged in business of pharmaceuticals.
SUNPHARMA
PE Ratio
36.50
36.50
1Y Return
4.00%
4.00%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.64
22.64
1Y Return
2.34%
2.34%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.13
59.13
1Y Return
13.13%
13.13%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
18.58
18.58
1Y Return
4.24%
4.24%
Buy Reco %
51.72
51.72
MANKIND
PE Ratio
52.73
52.73
1Y Return
18.31%
18.31%
Buy Reco %
81.25
81.25
NORRIS Forecast
NORRIS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NORRIS
NORRIS
Income
Balance Sheet
Cash Flow
Annual Normal View
NORRIS Income Statement
NORRIS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20.60 | 13.71 | 16.30 | 7.93 | 12.30 | 9.47 | 8.37 | 5.67 | 5.88 | 5.89 | ||||||||||
Raw Materials | 10.52 | 6.79 | 10.04 | 5.16 | 9.53 | 3.57 | 3.23 | 3.16 | 6.08 | 6.08 | ||||||||||
| Power & Fuel Cost | 1.63 | 1.62 | 1.54 | 1.22 | 0.97 | 0.81 | 0.90 | 0.76 | ||||||||||||
| Employee Cost | 5.31 | 4.93 | 3.81 | 3.23 | 3.10 | 2.33 | 2.30 | 1.82 | ||||||||||||
| Selling & Administrative Expenses | 1.29 | 1.17 | 0.72 | 0.55 | 0.68 | 0.39 | 0.43 | 0.34 | ||||||||||||
| Operating & Other expenses | 1.78 | 0.98 | 0.77 | -0.17 | -0.29 | 2.41 | 0.57 | -0.26 | ||||||||||||
EBITDA | 0.07 | -1.78 | -0.58 | -2.06 | -1.69 | -0.04 | 0.94 | -0.15 | -0.20 | -0.19 | ||||||||||
| Depreciation/Amortization | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.53 | ||||||||||
| PBIT | -0.58 | -2.49 | -1.29 | -2.79 | -2.36 | -0.70 | 0.31 | -0.72 | -0.74 | -0.72 | ||||||||||
| Interest & Other Items | 0.60 | 0.70 | 0.73 | 0.88 | 1.63 | 1.48 | 1.50 | 0.37 | 0.44 | 0.43 | ||||||||||
| PBT | -1.18 | -3.19 | -2.02 | -3.67 | -3.99 | -2.18 | -1.19 | -1.09 | -1.18 | -1.15 | ||||||||||
| Taxes & Other Items | -0.42 | -0.67 | -0.33 | -0.84 | 0.97 | 1.08 | 0.56 | 0.09 | 0.06 | 0.06 | ||||||||||
| Net Income | -0.76 | -2.52 | -1.69 | -2.83 | -4.96 | -3.26 | -1.75 | -1.18 | -1.24 | -1.21 | ||||||||||
| EPS | -0.77 | -2.54 | -1.70 | -2.85 | -5.00 | -3.28 | -1.76 | -1.18 | -1.24 | -1.21 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NORRIS Company Updates
NORRIS Stock Peers
NORRIS Past Performance & Peer Comparison
NORRIS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Norris Medicines Ltd | -14.28 | -1.30 | — |
| Sun Pharmaceutical Industries Ltd | 36.50 | 5.50 | 0.96% |
| Cipla Ltd | 22.64 | 3.82 | 1.08% |
| Torrent Pharmaceuticals Ltd | 59.13 | 14.89 | 0.18% |
NORRIS Stock Price Comparison
Compare NORRIS with any stock or ETFCompare NORRIS with any stock or ETF
NORRIS
NORRIS Holdings
NORRIS Shareholdings
NORRIS Promoter Holdings Trend
NORRIS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NORRIS Institutional Holdings Trend
NORRIS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NORRIS Shareholding Pattern
NORRIS Shareholding Pattern
NORRIS Shareholding History
NORRIS Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NORRIS stock
smallcases containing NORRIS stock
Looks like this stock is not in any smallcase yet.
NORRIS Events
NORRIS Events
NORRIS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NORRIS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NORRIS Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NORRIS has not given any dividends in last 5 years
NORRIS Dividends
NORRIS Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNORRIS Stock News & Opinions
NORRIS Stock News & Opinions
Articles & Videos
Earnings
Norris Medicines reports standalone net loss of Rs 0.23 crore in the March 2025 quarter
Net loss of Norris Medicines reported to Rs 0.23 crore in the quarter ended March 2025 as against net profit of Rs 0.17 crore during the previous quarter ended March 2024. Sales rose 82.55% to Rs 2.72 crore in the quarter ended March 2025 as against Rs 1.49 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 1.24 crore in the year ended March 2025 as against net loss of Rs 1.19 crore during the previous year ended March 2024. Sales rose 3.19% to Rs 5.82 crore in the year ended March 2025 as against Rs 5.64 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2.721.49 83 5.825.64 3 OPM %2.5732.21 --4.47-3.37 - PBDT-0.030.40 PL -0.64-0.53 -21 PBT-0.170.26 PL -1.18-1.10 -7 NP-0.230.17 PL -1.24-1.19 -4 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Norris Medicines to discuss results
Norris Medicines will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Norris Medicines reports standalone net loss of Rs 0.28 crore in the December 2024 quarter
Net Loss of Norris Medicines reported to Rs 0.28 crore in the quarter ended December 2024 as against net loss of Rs 0.27 crore during the previous quarter ended December 2023. Sales rose 70.77% to Rs 1.11 crore in the quarter ended December 2024 as against Rs 0.65 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1.110.65 71 OPM %-2.70-6.15 - PBDT-0.15-0.13 -15 PBT-0.28-0.27 -4 NP-0.28-0.27 -4 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Norris Medicines to declare Quarterly Results
Norris Medicines will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Norris Medicines reports standalone net loss of Rs 0.36 crore in the September 2024 quarter
Net Loss of Norris Medicines reported to Rs 0.36 crore in the quarter ended September 2024 as against net loss of Rs 0.48 crore during the previous quarter ended September 2023. Sales declined 50.39% to Rs 1.27 crore in the quarter ended September 2024 as against Rs 2.56 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1.272.56 -50 OPM %-11.81-9.77 - PBDT-0.23-0.34 32 PBT-0.36-0.48 25 NP-0.36-0.48 25 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Norris Medicines to table results
Norris Medicines will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Norris Medicines to conduct AGM
Norris Medicines announced that the 33th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Norris Medicines reports standalone net loss of Rs 0.37 crore in the June 2024 quarter
Net Loss of Norris Medicines reported to Rs 0.37 crore in the quarter ended June 2024 as against net loss of Rs 0.61 crore during the previous quarter ended June 2023. Sales declined 24.21% to Rs 0.72 crore in the quarter ended June 2024 as against Rs 0.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.720.95 -24 OPM %-23.61-40.00 - PBDT-0.24-0.47 49 PBT-0.37-0.61 39 NP-0.37-0.61 39 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Norris Medicines to discuss results
Norris Medicines will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Norris Medicines reports standalone net loss of Rs 0.05 crore in the June 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of -5.81%, vs industry avg of 10.1%
Over the last 5 years, market share stayed at 0%